BCAX - NASDAQ

Bicara Therapeutics Inc. Common Stock

BCAX·NASDAQ

$20.52

+4.5%

HealthcareBiotechnology

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.12B

EPS-2.5200

P/E Ratio-8.14

Earnings Date08/11/2026

bcax

Income Tax Expense

Last Annual Value

217.00K

3-Year CAGR

501%

5-Year CAGR

193%

10-Year CAGR

71%

Adjust for Inflation

Bicara Therapeutics Inc. Common Stock Competitors Analysis of Income Tax Expense

BCAX · NASDAQ

Company	Income Tax Expense	CAGR 3Y	CAGR 5Y	CAGR 10Y
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	217.00K	251.4%	N/A	N/A
Fortrea Holdings Inc. NASDAQ:FTRE	3.20M	38.7%	-39.2%	N/A
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT	0.00	N/A	N/A	N/A
Prime Medicine, Inc. NASDAQ:PRME	0.00	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	279.00K	49.8%	N/A	N/A
ProKidney Corp. NASDAQ:PROK	414.00K	-59.0%	61.2%	N/A
Savara Inc. NASDAQ:SVRA	0.00	N/A	N/A	N/A
Tango Therapeutics, Inc. NASDAQ:TNGX	4.00K	-69.0%	-57.6%	N/A
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	-4.21M	N/A	N/A	N/A
Kura Oncology, Inc. NASDAQ:KURA	297.00K	N/A	N/A	N/A
Septerna, Inc. NASDAQ:SEPN	12.00K	-74.1%	N/A	N/A

Bicara Therapeutics Inc. Common Stock Fair Value Envelope

BCAX · NASDAQ

Our analysis suggests that BCAX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $20.52, this represents a potential HIDDEN relative to our calculated worth for Bicara Therapeutics Inc. Common Stock.

HIDDEN

Intrinsic Value

Current Price: $20.52

Related Guides

Blog Categories

Continue your BCAX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.